Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Knowledge to Action: Developing a Knowledge Translation Strategy to Improve Screening, Diagnosis, and Treatment of Familial Hypercholesterolemia in British Columbia Based on the New 2022 Canadian Pediatric Lipid Guidelines
EF 2022-23
Résumé
Familial Hypercholesterolemia (FH) is an under-diagnosed genetic condition where cholesterol is improperly used by the body and exists at dangerously high levels in the blood. FH is common, occurring in approximately 1 in 250 people in Canada. Excess cholesterol causes harmful plaques inside blood vessels, interfering with circulatory health. Plaque build-up causes life-threatening events like heart attacks and strokes in young adults which are preventable with early diagnosis and treatment.
FH is clinically silent, meaning that no symptoms appear until a major cardiac event occurs. Without detection of abnormal cholesterol in childhood, uncontrolled plaque build-up shortens lives by several decades.
FH can easily be detected with a blood test, though screening is not currently routinely used. Because of the lack of screening and the fact that FH is clinically silent, approximately 90% of cases are not diagnosed during childhood. In response, the Canadian Cardiovascular Society published new guidelines recommending screening of all children aged 9-11 for elevated cholesterol. If FH is identified and treated in childhood, cardiac events can be prevented.
Using population health data for children under 18, my project will define baseline percentages and demographics of children currently being screened, diagnosed, and treated for FH in British Columbia. Having established a baseline, my research will engage family doctors and pediatricians to adopt the new guidelines through development of a knowledge translation initiative. Webinars and learning assessments for physicians will be used to increase awareness and usage of guidelines. Enhancing detection and treatment of FH in children has the potential to significantly improve and protect the futures of these patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486221
Name
Thorsen Venessa K
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Knowledge to Action: Developing a Knowledge Translation Strategy to Improve Screening, Diagnosis, and Treatment of Familial Hypercholesterolemia in British Columbia Based on the New 2022 Canadian Pediatric Lipid Guidelines
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cardiovascular; Cholesterol; Clinical Guidelines; Diagnosis; Familial Hypercholesterolemia; Knowledge Translation; Pediatric; Preventive; Screening; Treatment
Abstract
Familial Hypercholesterolemia (FH) is an under-diagnosed genetic condition where cholesterol is improperly used by the body and exists at dangerously high levels in the blood. FH is common, occurring in approximately 1 in 250 people in Canada. Excess cholesterol causes harmful plaques inside blood vessels, interfering with circulatory health. Plaque build-up causes life-threatening events like heart attacks and strokes in young adults which are preventable with early diagnosis and treatment.
FH is clinically silent, meaning that no symptoms appear until a major cardiac event occurs. Without detection of abnormal cholesterol in childhood, uncontrolled plaque build-up shortens lives by several decades.
FH can easily be detected with a blood test, though screening is not currently routinely used. Because of the lack of screening and the fact that FH is clinically silent, approximately 90% of cases are not diagnosed during childhood. In response, the Canadian Cardiovascular Society published new guidelines recommending screening of all children aged 9-11 for elevated cholesterol. If FH is identified and treated in childhood, cardiac events can be prevented.
Using population health data for children under 18, my project will define baseline percentages and demographics of children currently being screened, diagnosed, and treated for FH in British Columbia. Having established a baseline, my research will engage family doctors and pediatricians to adopt the new guidelines through development of a knowledge translation initiative. Webinars and learning assessments for physicians will be used to increase awareness and usage of guidelines. Enhancing detection and treatment of FH in children has the potential to significantly improve and protect the futures of these patients.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Thorsen, Venessa K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~